Liraglutide Decreases Liver Fat Content and Serum Fibroblast Growth Factor 21 Levels in Newly Diagnosed Overweight Patients with Type 2 Diabetes and Nonalcoholic Fatty Liver Disease
Purposes. In this study, we aimed to verify plasma fibroblast growth factor 21 (FGF21) elevation in newly diagnosed overweight patients with type 2 diabetes mellitus (T2DM) and nonalcoholic fatty liver disease (NAFLD) and to evaluate the effectiveness of liraglutide on reducing liver fat content and...
Saved in:
Main Authors: | Xinyue Li, Xiaojuan Wu, Yumei Jia, Jing Fu, Lin Zhang, Tao Jiang, Jia Liu, Guang Wang |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2021-01-01
|
Series: | Journal of Diabetes Research |
Online Access: | http://dx.doi.org/10.1155/2021/3715026 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The Effectiveness of Liraglutide in Nonalcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus Compared to Sitagliptin and Pioglitazone
by: Takamasa Ohki, et al.
Published: (2012-01-01) -
Liraglutide Attenuates Nonalcoholic Fatty Liver Disease through Adjusting Lipid Metabolism via SHP1/AMPK Signaling Pathway
by: Peng Yu, et al.
Published: (2019-01-01) -
The effects of liraglutide on liver enzymes
and metabolic factors in patients with nonalcoholic steatohepatitis: a meta-analysis of randomized controlled trials
by: Adnan Malik, et al.
Published: (2022-01-01) -
Current Treatment Options for Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis
by: Melanie D Beaton
Published: (2012-01-01) -
Nonalcoholic Fatty Liver Disease in Patients Investigated for Elevated Liver Enzymes
by: Krikor Kichian, et al.
Published: (2003-01-01)